Listed

Sunshine Biopharma Inc.: Form 10-Q for the period ended Mar 31, 2013

Filed with the SEC on May 9, 2013 and accepted by EDGAR at May 9, 2013, 12:12 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2013-01-01 to 2013-03-31$23.4kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2013-01-01 to 2013-03-31−$922.9kus-gaap:OperatingIncomeLoss
Interest expense3 months2013-01-01 to 2013-03-31$5.3kus-gaap:InterestExpense
Net income3 months2013-01-01 to 2013-03-31−$1.5mus-gaap:NetIncomeLoss
Basic EPS3 months2013-01-01 to 2013-03-31−$0.03us-gaap:EarningsPerShareBasic
Operating cash flow3 months2013-01-01 to 2013-03-31−$339.7kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2013-03-31$255.9kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-03-31$259.0kus-gaap:AssetsCurrent
Total assetsAt period end2013-03-31$259.0kus-gaap:Assets
Total liabilitiesAt period end2013-03-31$22.4kus-gaap:Liabilities
Shareholders' equityAt period end2013-03-31$236.6kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001354488-13-002516. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.